Biofrontera Inc. (BFRIW) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.5x

Market Cap

$215534.78

MomentumView details →

1D Return

−25.93%

YTD Return

−75.56%

RSI (14)

42.9

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.5x

Market Cap

$215534.78

RSI (14)

42.9

MomentumView details →

1D Return

−25.93%

YTD Return

−75.56%

ProfitabilityView details →

Gross Margin

84.45%

Net Margin

−13.78%

EBITDA Margin

−12.19%

ROE (TTM)

−106.87%

ROA (TTM)

−26.45%

Asset Turnover

1.89x

GrowthView details →

Revenue YoY

+17.83%

EPS YoY

+76.00%

FCF YoY

+15.57%

Revenue CAGR 3Y

+13.30%

EPS CAGR 3Y

+67.70%

EBITDA YoY

+63.21%

EarningsView details →

EPS (Actual)

−$0.05

EPS Surprise

52.38%

Beats (12Q)

2/12

Next Q EPS Est

−$0.22

Avg Surprise (4Q)

−16.09%

Rev Surprise

26.35%

Capital & dividendView details →

Debt/Equity

1.26x

Current Ratio

1.18x

Quick Ratio

1.08x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

46.17M

Net Income (TTM)

−6.37M

Op. CF (TTM)

−7.93M

Next earningsNov 18, 2026 →

Latest newsMore news →

Biofrontera Inc. reported its financial results for the second quarter of 2026, highlighting a 33% revenue growth.24d ago

Similar companies

Petros Pharmaceuticals, Inc.PTPI Sunshine Biopharma, Inc.SBFMW ProPhase Labs, Inc.PRPH China SXT Pharmaceuticals, Inc.SXTC IM Cannabis Corp.IMCC Akanda Corp.AKAN Find similar companies →

Latest newsMore news →

Biofrontera Inc. reported its financial results for the second quarter of 2026, highlighting a 33% revenue growth.24d ago